Skip to content

Clincal trial of optimized regimen of Chinese traditional medicine in treatment of patients with Knee osteoarthritis

Clincal trial of optimized regimen of Chinese traditional medicine in treatment of patients with Knee osteoarthritis

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-08000176
Enrollment
Unknown
Registered
2008-01-23
Start date
2008-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

Group A:Apply the TCM compound cream of Fufang Zijin Xiaoshang Gao (Lei's) on skin, two days for one, total 4 weeks.
Group B:Multiple therapy will be used: additional to oral TCM Kang Guzengsheng capsule, acupuncture and massage and the compund cream Fufang Zijin Xiaoshang Gao will be used according to the status of
Group C:TCM Kang Guzhengsheng Capsule (Kangyuan company), oral two capsules, t.i.d., 4 weeks.
Group D:Standard operation of massage therapy
Group E:Standard operation of massage therapy

Sponsors

Shuguang Hospital Affiliated to Shanghai Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
38 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged from 38 to 70; 2. Knee osteoarthritis patients with typical osteoarthritis symptoms, also with TCM "jinmai yuzhi zheng"; 3. Participants attend the trial of their own free will and sign the informed consent form before treatment.

Exclusion criteria

Exclusion criteria: 1. Patients with primary severe heart, brain,kidney, lung, liver, hematopoietic system disease; 2. Patients treated with other drug or Therapy which affect conclusion of the study 3. Patients with rheumatoid arthritis,gouty arthritis,inflammatory arthritis; 4. Pregnant patients or women need fertilization, women in lactation period; 5. Patients allergic to the drug used in this study; 6. Patients enrolled in another clinical trial.

Design outcomes

Primary

MeasureTime frame
WOMAc-VA3.1;

Secondary

MeasureTime frame
SF-36TCM symptom questionnairy;

Countries

China

Contacts

Public ContactZhan hongsheng
shgsyjs@vip.sina.com+86 021 51328888-8420

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026